Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Invokana, Invokamet, Vokanamet
Canagliflozin is an oral anti-diabetic drug belonging to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class. It works by preventing the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. This mechanism is independent of insulin secretion or action, making it effective in patients with type 2 diabetes mellitus (T2DM) even when insulin resistance is present.
For improving glycemic control in adults with type 2 diabetes mellitus, reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease, and reducing the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and/or cardiovascular disease.
Increased risk of lower limb amputation, particularly of the toe.
Outcome:
Increased risk of hypoglycemia
Mechanism:
Additive hypoglycemic effects
Outcome:
Reduced efficacy of canagliflozin
Mechanism:
NSAIDs may reduce renal blood flow and decrease canagliflozin excretion
Outcome:
No clinically significant interaction
Mechanism:
Unknown
Most likely new formulation: Extended-release canagliflozin (2025, 75% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood that canagliflozin will maintain its current FDA approval status for the next 5 years.
Antidiabetic, SGLT2 Inhibitor
Benzopyran derivative